Consolidated Statements of Income (USD $) In Millions, except Per Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Revenues:
Product sales	$ 5,830.4		$ 4,757.5		$ 4,252.9
Royalties	160.8		153.7		241.6
Other revenues	30.9		23.1		32.9
Total revenues	6,022.1		4,934.3		4,527.4
Costs and expenses:
Cost of product sales	979.3		670.8		585.8
Research and development	1,067.5	[1]	933.4	[1]	953.0	[1]
Selling, general and administrative	2,025.8	[1]	1,651.3	[1]	1,948.0	[1]
Goodwill impairment charge	0		7.1		0
Gain on sale of product rights	(88.2)		(15.9)		(18.1)
Reorganization costs	180.9		88.2		0
Integration and acquisition costs	158.8		(134.1)		13.5
Total operating expenses	4,324.1		3,200.8		3,482.2
Operating income from continuing operations	1,698.0		1,733.5		1,045.2
Interest income	24.7		2.1		3.0
Interest expense	(30.8)		(38.1)		(38.2)
Other income/(expense), net	8.9		(3.9)		(2.2)
Receipt of break fee	1,635.4		0		0
Income from continuing operations before income taxes and equity in earnings of equity method investees	3,336.2		1,693.6		1,007.8
Income taxes	(56.1)		(277.9)		(203.1)
Equity in earnings of equity method investees, net of taxes	2.7		3.9		1.0
Income from continuing operations, net of taxes	3,282.8		1,419.6		805.7
Gain/(loss) from discontinued operations, net of taxes	122.7		(754.5)		(60.3)
Net income	$ 3,405.5		$ 665.1		$ 745.4
Earnings from continuing operations (in USD per share)	$ 5.596		$ 2.572		$ 1.451
Gain/(loss) from discontinued operations (in USD per share)	$ 0.209		$ (1.367)		$ (0.109)
Earnings per ordinary share - basic (in USD per share)	$ 5.805		$ 1.205		$ 1.342
Earnings from continuing operations (in USD per share)	$ 5.552		$ 2.453		$ 1.410
Gain/(loss) from discontinued operations (in USD per share)	$ 0.208		$ (1.278)		$ (0.101)
Earnings per ordinary share - diluted (in USD per share)	$ 5.760		$ 1.175		$ 1.309
Weighted average number of shares:
Basic (in shares)	586.7	[2]	552.0	[2]	555.4	[2]
Diluted (in shares)	591.3		590.3		593.5

[1] Research and development (“R&D”) includes intangible asset impairment charges of $190.3 million for the year to December 31, 2014 (2013: $19.9 million, 2012: $71.2 million). Selling, general and administrative (“SG&A”) costs include amortization of intangible assets relating to intellectual property rights acquired of $243.8 million for the year to December 31, 2014 (2013: $152.0 million, 2012: $280.3 million).

[2] Excludes shares purchased by the EBT and presented by Shire as treasury stock